| Heart disease and stroke statistics—2015 update: a report from the American Heart Association D Mozaffarian, EJ Benjamin, AS Go, DK Arnett, MJ Blaha, M Cushman, ... circulation 131 (4), e29-e322, 2015 | 27101* | 2015 |
| Heart disease and stroke statistics—2012 update: a report from the American Heart Association Writing Group Members, VL Roger, AS Go, DM Lloyd-Jones, EJ Benjamin, ... Circulation 125 (1), e2-e220, 2012 | 22895* | 2012 |
| Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis AB Rossebø, TR Pedersen, K Boman, P Brudi, JB Chambers, K Egstrup, ... New England journal of medicine 359 (13), 1343-1356, 2008 | 1692 | 2008 |
| Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in … K Wachtell, M Lehto, E Gerdts, MH Olsen, B Hornestam, B Dahlöf, H Ibsen, ... Journal of the American College of Cardiology 45 (5), 712-719, 2005 | 1104 | 2005 |
| Prognostic significance of left ventricular mass change during treatment of hypertension RB Devereux, K Wachtell, E Gerdts, K Boman, MS Nieminen, ... Jama 292 (19), 2350-2356, 2004 | 994 | 2004 |
| Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study H Ibsen, MH Olsen, K Wachtell, K Borch-Johnsen, LH Lindholm, ... Hypertension 45 (2), 198-202, 2005 | 926* | 2005 |
| Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study K Wachtell, H Ibsen, MH Olsen, K Borch-Johnsen, LH Lindholm, ... Annals of internal medicine 139 (11), 901-906, 2003 | 725 | 2003 |
| Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial RB Devereux, B Dahlöf, E Gerdts, K Boman, MS Nieminen, ... Circulation 110 (11), 1456-1462, 2004 | 652 | 2004 |
| Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study LH Lindholm, H Ibsen, K Borch-Johnsen, MH Olsen, K Wachtell, B Dahlöf, ... Journal of hypertension 20 (9), 1879-1886, 2002 | 525 | 2002 |
| A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension MH Olsen, SY Angell, S Asma, P Boutouyrie, D Burger, JA Chirinos, ... The Lancet 388 (10060), 2665-2712, 2016 | 446 | 2016 |
| Prevention of atrial fibrillation by renin-angiotensin system inhibition: a meta-analysis MP Schneider, TA Hua, M Böhm, K Wachtell, SE Kjeldsen, RE Schmieder Journal of the American College of Cardiology 55 (21), 2299-2307, 2010 | 444 | 2010 |
| Risk prediction is improved by adding markers of subclinical organ damage to SCORE T Sehestedt, J Jeppesen, TW Hansen, K Wachtell, H Ibsen, ... European heart journal 31 (7), 883-891, 2010 | 390 | 2010 |
| Outcome of patients with low-gradient “severe” aortic stenosis and preserved ejection fraction N Jander, J Minners, I Holme, E Gerdts, K Boman, P Brudi, JB Chambers, ... Circulation 123 (8), 887-895, 2011 | 349 | 2011 |
| Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension PM Okin, K Wachtell, RB Devereux, KE Harris, S Jern, SE Kjeldsen, ... Jama 296 (10), 1242-1248, 2006 | 319 | 2006 |
| Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE … K Wachtell, B Hornestam, M Lehto, DJ Slotwiner, E Gerdts, MH Olsen, ... Journal of the American College of Cardiology 45 (5), 705-711, 2005 | 293 | 2005 |
| CLINICAL PERSPECTIVE K Wachtell, PM Okin, MH Olsen, B Dahlöf, RB Devereux, H Ibsen, ... Circulation 116 (7), 700-705, 2007 | 281 | 2007 |
| Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study E Gerdts, L Oikarinen, V Palmieri, JE Otterstad, K Wachtell, K Boman, ... Hypertension 39 (3), 739-743, 2002 | 267 | 2002 |
| Short-and long-term cause of death in patients treated with primary PCI for STEMI F Pedersen, V Butrymovich, H Kelbæk, K Wachtell, S Helqvist, J Kastrup, ... Journal of the American College of Cardiology 64 (20), 2101-2108, 2014 | 259 | 2014 |
| Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: the LIFE study K Wachtell, JN Bella, PR Liebson, E Gerdts, B Dahlöf, T Aalto, ... Hypertension 35 (1), 6-12, 2000 | 247 | 2000 |
| Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial E Gerdts, K Wachtell, P Omvik, JE Otterstad, L Oikarinen, K Boman, ... Hypertension 49 (2), 311-316, 2007 | 244 | 2007 |
